Steven Mark Sorscher (Steven Sorscher)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 42

Top Topics

Tyrosine Kinase

Helicobacter Pylori

Top Venues

Breast cancer research and treatment

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of breast cancer

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Steven Mark Sorscher
Inadequate Uptake of USPSTF-Recommended Low Dose CT Lung Cancer Screening. Journal of primary care & community health 15 (2024)
Steven Mark Sorscher
Comment on Giraudo et al. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? Cancers 2024, 16 , 1838. Cancers 16 (16) (2024)
Steven Mark Sorscher
Clinical Utility of Circulating Tumor DNA Assays. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Steven Mark Sorscher
Comment on Giraudo et al. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? Cancers 2024, 16 , 1838. Cancers 16 (16) (2024)
Steven Mark Sorscher
Dangers of Artificial Intelligence in Oncology. JCO oncology practice 20 (3) (2024)
Steven Mark Sorscher
Omission of Radiotherapy for Women With Low-Risk Invasive Cancers That Have a Ductal Carcinoma In Situ Component. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (16) (2024)
Steven Mark Sorscher
Omission of Radiotherapy for Women With Low-Risk Invasive Cancers That Have a Ductal Carcinoma In Situ Component. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Steven Mark Sorscher
Dangers of Artificial Intelligence in Oncology. JCO oncology practice 20 (3) (2024)
Steven Mark Sorscher
Helicobacter pylori and Gastric Cancer Screening. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Steven Mark Sorscher
Is Adjuvant Chemotherapy Preceding Cyclin-Dependent Kinase 4/6 Inhibitor Therapy Beneficial? Journal of breast cancer (2024)
Steven Mark Sorscher
Inadequate Uptake of USPSTF-Recommended Low Dose CT Lung Cancer Screening. Journal of primary care & community health 15 (2024)
Steven Mark Sorscher
Dangers of Artificial Intelligence in Oncology. JCO oncology practice (2024)
Steven Mark Sorscher
Why the length of recurrence-free survival or 'lead-times' can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Therapeutic advances in medical oncology 15 (2023)
Steven Mark Sorscher
Mitigating fear of cancer recurrence. Breast cancer research and treatment 198 (2) (2023)
Steven Mark Sorscher
Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States". Advances in therapy (2023)
Steven Mark Sorscher
Mitigating fear of cancer recurrence. Breast cancer research and treatment 198 (2) (2023)
Steven Mark Sorscher
Mitigating fear of cancer recurrence. Breast cancer research and treatment 198 (2) (2023)
Steven Mark Sorscher
Clinicopathologic and Molecular Subtyping of EGFR Mutation-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (3) (2023)
Steven Mark Sorscher
Clinicopathologic and Molecular Subtyping of EGFR Mutation-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (3) (2023)
Steven Mark Sorscher
Why the length of recurrence-free survival or 'lead-times' can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Therapeutic advances in medical oncology 15 (2023)
Steven Mark Sorscher
Do All Patients Diagnosed With Cancer Deserve Germline Testing? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Steven Mark Sorscher
Mitigating fear of cancer recurrence. Breast cancer research and treatment (2023)
Steven Mark Sorscher
Mitigating fear of cancer recurrence. Breast cancer research and treatment 198 (2) (2023)
Steven Mark Sorscher
Clinicopathologic and Molecular Subtyping of EGFR Mutation-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (3) (2023)
Steven Mark Sorscher, Jaclyn LoPiccolo, Brandie H Leach, Elaine Chen, Robert L Nussbaum, Scott T Michalski, Sarah M Nielsen, Alix M B Lacoste, Emil Keyder, Hayan Lee, Robert Luke Nussbaum, Renato G Martins, Edward D Esplin
Rate of Pathogenic Germline Variants in Patients With Lung Cancer. JCO precision oncology 7 (2023)
Steven Mark Sorscher
Is It Time to Expand Our Definition of "Clinical Utility"? Cancer control : journal of the Moffitt Cancer Center 30 (2023)
Steven Mark Sorscher
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. Journal of breast cancer 26 (1) (2022)
Steven Mark Sorscher
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. Journal of breast cancer 26 (1) (2022)
Steven Mark Sorscher
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. Journal of breast cancer 26 (1) (2022)
Steven Mark Sorscher
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. Journal of breast cancer 26 (1) (2022)
Steven Mark Sorscher
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. Journal of breast cancer (2022)
Steven Mark Sorscher
Why it is our responsibility to speak out for a universal vaccination mandate. Cancer (2021)
Steven Mark Sorscher
Patients With Group2, HER2-Negative Tumors on ALTERNATIVE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (10) (2021)
Steven Mark Sorscher, Shakti Ramkissoon
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant. The oncologist 26 (11) (2021)
Steven Mark Sorscher
The parallel in public health crises between not banning tobacco and not requiring face masks during the COVID-19 pandemic. Cancer 127 (5) (2020)
Steven Mark Sorscher
To treat or not to treat, that is the question. Health psychology open 7 (2) (2020)
Steven Mark Sorscher
Biomarkers for CDK4/6 inhibitor efficacy. The breast journal 27 (1) (2020)
Steven Mark Sorscher, Katherine Ansley, Steven Douglas Delaney, Shakti Ramkissoon
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). Breast cancer research and treatment 180 (2) (2020)
Steven Mark Sorscher
My stray dog memory. The breast journal 26 (9) (2020)
Steven Mark Sorscher
Circulating cell-free DNA use for diagnosing cholangiocarcinoma. Clinical epigenetics 11 (1) (2019)
Steven Mark Sorscher
Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression. Breast cancer research and treatment 178 (2) (2019)
Steven Mark Sorscher
Reclassifying HER2-equivocal disease. Breast cancer research and treatment 167 (3) (2017)